A Biotech With Over 300% Potential Upside
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is a clinical-stage biotechnology company that has caught the attention of investors with its promising pipeline and substantial potential upside of over 300%. Specializing in innovative mRNA cell therapies for autoimmune diseases, the company operates at the forefront of biotech innovation. Headquartered in Frederick, Maryland, Cartesian Therapeutics is currently focusing on its lead product candidate, Descartes-08, which is making significant strides in Phase 2b clinical trials.
**Current Market Position and Valuation**
Cartesian Therapeutics holds a market capitalization of $233.76 million, reflecting its position as a promising yet speculative player in the biotechnology sector. Its…
